Low vaccination rates for influenza viruses and the lack of an HSV vaccine underscore the need for a new approach to reduce viral transmission. Researchers have now used a clinical-grade antiviral ...

A new cancer therapy utilising a genetically modified herpes simplex virus type 1 (HSV-1) offers hope for late-stage patients, especially those resistant to existing immunotherapies.

A team of US researchers have developed a new antiviral chewing gum that showed the potential to substantially reduce viral loads of two herpes simplex viruses and two influenza A strains ...

More than five years since COVID was declared a pandemic, we’re still facing the regular emergence of new variants of the virus, SARS-CoV-2. The latest variant on the rise is LP.8.1. It’s increasing ...